Related Experiment Video

Updated: Nov 10, 2025

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

799

Immune Check Point Inhibitors and Immune-Related Adverse Events in Small Cell Lung Cancer

Wanting Hou1, Xiaohan Zhou1, Cheng Yi1

  • 1Department of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, China.

Frontiers in Oncology
|April 5, 2021
PubMed

Insights

Immune checkpoint inhibitors (ICIs) offer advances in treating small cell lung cancer (SCLC), but can cause immune-related adverse events (irAEs). Understanding these irAEs is crucial for managing SCLC patients effectively.

Area of Science:

  • Oncology
  • Immunology
  • Cancer Therapeutics

Background:

  • Small cell lung cancer (SCLC) is a significant malignant solid tumor.
  • Immune checkpoint inhibitors (ICIs) represent a therapeutic advance for SCLC.
  • Immune-related adverse events (irAEs) are a concern with ICI therapy in SCLC.

Purpose of the Study:

  • To provide an updated overview of ICIs in SCLC treatment.
  • To detail the immune-related adverse events (irAEs) associated with ICIs in SCLC.
  • To highlight the importance of understanding irAEs for clinical management of SCLC.

Main Methods:

  • Review of current clinical data on ICIs in SCLC.
  • Analysis of reported immune-related adverse events (irAEs).
  • Synthesis of information regarding the SCLC immune microenvironment.

Main Results:

  • ICIs have shown promise in SCLC treatment.
  • Various irAEs occur during ICI therapy, sometimes necessitating dose reduction or discontinuation.
  • The complex immune microenvironment of SCLC influences irAEs.

Conclusions:

  • Comprehensive understanding of irAEs is vital for optimizing ICI therapy in SCLC.
  • Further research is needed to fully elucidate irAEs in the context of SCLC.
  • Effective management strategies for irAEs are essential for patient care in SCLC.
Keywords:
cytotoxic T lymphocyte-associated antigen 4 (CTLA-4)immune check point inhibitors (ICIs)immune-related adverse events (irAEs)programmed cell death ligand protein 1 (PD-L1)programmed cell death protein 1 (PD-1)small cell lung cancer

More Related Videos

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence10:29

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

10.8K
Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood06:07

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Published on: February 5, 2020

5.9K

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
818
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.0K